Advertisement

Dyslipidemias pp 423-438 | Cite as

Fibrates: Risk Benefits and Role in Treating Dyslipidemias

  • Min JunEmail author
  • Vlado Perkovic
Chapter
Part of the Contemporary Endocrinology book series (COE)

Abstract

There is a strong causative relationship between lipids and cardiovascular disease. The strongest body of evidence has been centered on the relationship of elevated concentrations of both total cholesterol and low-density lipoprotein (LDL) cholesterol with major cardiovascular outcomes. However, it is now widely recognized that LDL cholesterol is not the only atherogenic constituent of the lipid subfraction and that derangements in triglyceride and high-density lipoprotein (HDL) cholesterol concentrations are strong predictors for poor cardiovascular outcomes. For more than four decades, fibrates have been shown to effectively reduce triglyceride and elevate HDL-cholesterol concentrations. Fibrates are thus recommended as the primary treatment option for the management of hypertriglyceridemia and have also been suggested as an ideal pharmacotherapy aimed at reducing the residual cardiovascular risk observed in patients with mixed dyslipidemia. In spite of this, large outcome trials evaluating the effects of fibrates on major cardiovascular events have reported mixed results. In addition, although rare, reports of adverse effects, particularly when combined with statins, have limited the wider use of fibrates as lipid-lowering agents. However, recent meta-analyses, combining the outcome data from trials to date and post hoc analyses of large randomized controlled trials have reported significant cardiovascular benefits from fibrate therapy, showing risk reductions in major cardiovascular events, primarily as a consequence of a favorable effect on the risk of coronary events. In addition, recent studies have consistently reported that people with elevated triglyceride concentrations benefited the most from fibrate therapy, suggesting that while the overall risk reduction may be moderate compared to statin therapy, a substantially greater magnitude of benefit may exist in this subset of patients. These results suggest that fibrates have an important role in individualized approaches to management of patients at high risk of cardiovascular disease with mixed dyslipidemia.

Keywords

Fibrates Hypertriglyceridemia Lipid lowering Fenofibrate Gemfibrozil Bezafibrate 

References

  1. 1.
    Mendis S, Puska P, Norrving B, World Health Organization, World Heart Federation, World Stroke Organization. 2011. World health organization. Global atlas on cardiovascular disease prevention and control. Geneva.Google Scholar
  2. 2.
    LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Amer Coll Cardiol. 2008;52:1769–81.CrossRefGoogle Scholar
  4. 4.
    Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Amer J Med. 2009;122:e1–8.CrossRefPubMedGoogle Scholar
  5. 5.
    ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.CrossRefGoogle Scholar
  6. 6.
    BIP Study Group. Secondary preventiosn by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–7.CrossRefGoogle Scholar
  7. 7.
    Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.CrossRefPubMedGoogle Scholar
  8. 8.
    WHO Cooperative trial committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. 1978;40:1069–118.CrossRefGoogle Scholar
  9. 9.
    Amend KL, Landon J, Thyagarajan V, et al. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother. 2011;45:1230–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature. 1962;194:948–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Thorp JM. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate. Lancet. 1962;1:1323–6.CrossRefGoogle Scholar
  13. 13.
    Oliver MF. Reduction of serum-lipid and uric-acid levels by an orally active androsterone. Lancet. 1962;1:1321–3.CrossRefPubMedGoogle Scholar
  14. 14.
    Denborough MA, Lovell RR, Trevaks G. The effect of chlorophenoxyisobutyric acid ester with androsterone on plasma lipids in women. MJA. 1963;50:498–501.PubMedGoogle Scholar
  15. 15.
    Hellman L, Zumoff B, Kessler G, et al. Reduction of Cholesterol and Lipids in Man by Ethyl P-Chlorophenoxyisobutyrate. Ann Intern Med. 1963;59:477–94.CrossRefPubMedGoogle Scholar
  16. 16.
    Hunninghake DB, Tucker DR, Azarnoff DL. Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation. 1969;39:675–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Witztum JL. Drugs used in the treatment of hyperlipoproteinemias: In Hardman JG, Limbaird LE, Editors. Goodman & Gilman’s the pharmacological basic of therapeutics. New York: McGraw-Hill; 1996. p. 875–97.Google Scholar
  18. 18.
    Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis. 1972;15:177–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. BMJ. 1971;4:775–84.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Arthur JB, Ashby DWR, Bremer C, et al. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ. 1971;4: 767–75.CrossRefGoogle Scholar
  21. 21.
    Coronary Drug Project Research Group. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA. 1972;220:996–1008.CrossRefGoogle Scholar
  22. 22.
    The Veterans Administration Cooperative Study Group. The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke. 1973;4:684–93.CrossRefGoogle Scholar
  23. 23.
    Schoonjans KB, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophysica Acta. 1996;1302:93–109.CrossRefGoogle Scholar
  24. 24.
    Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46:1319–27.CrossRefPubMedGoogle Scholar
  26. 26.
    Jones PS, Savory R, Barratt P, et al. Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. Eur J Biochem. 1995;233:219–26.CrossRefPubMedGoogle Scholar
  27. 27.
    Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790–3.CrossRefPubMedGoogle Scholar
  28. 28.
    Keller H, Dreyer C, Medin J, et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA. 1993;90:2160–4.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Skogsberg J, Kannisto K, Roshani L, et al. Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int J Mol Med. 2000;6:73–81.PubMedGoogle Scholar
  30. 30.
    Matsuura H, Adachi H, Smart RC, et al. Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol Cell Endocrinol. 1999;147:85–92.CrossRefPubMedGoogle Scholar
  31. 31.
    Westergaard M, Henningsen J, Svendsen ML, et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol. 2001;116:702–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Feige JN, Gelman L, Michalik L, et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res. 2006;45:120–59.CrossRefPubMedGoogle Scholar
  33. 33.
    Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4:611–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147–56.CrossRefPubMedGoogle Scholar
  35. 35.
    Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999;4:597–609.CrossRefPubMedGoogle Scholar
  36. 36.
    Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl co-enzyme A oxidase. J Clin Invest. 1995;95:705–712.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Milosavljevic D, Griglio S, Le Naour G, et al. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis. 2001;155:251–60.CrossRefPubMedGoogle Scholar
  38. 38.
    Fruchart JC, Brewer Jr HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Amer J Cardiol. 1998;81:912–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Berthou L, Staels B, Saldicco I, et al. Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression. Arterioscler Thromb. 1994;14:1657–64.CrossRefPubMedGoogle Scholar
  40. 40.
    Malmendier CL, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis. 1985;55:161–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Mellies MJ, Stein EA, Khoury P, et al. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia. Atherosclerosis. 1987;63:57–64.CrossRefPubMedGoogle Scholar
  42. 42.
    Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995;96:741–50.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998;34:155–62.CrossRefPubMedGoogle Scholar
  44. 44.
    Abshagen U, Bablok W, Koch K, et al. Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol. 1979;16:31–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther. 2002;24:2022–50.CrossRefPubMedGoogle Scholar
  46. 46.
    Knauf H, Kolle EU, Mutschler E. Gemfibrozil absorption and elimination in kidney and liver disease. Klin Wochenschr. 1990;68:692–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Corbelli JC, Bullano MF, Willey VJ, et al. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy. Amer J Cardiol. 2002;90:1388–91.CrossRefPubMedGoogle Scholar
  48. 48.
    Packard KA, Backes JM, Lenz TL, et al. Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacotherapy. 2002;22:1527–32.CrossRefPubMedGoogle Scholar
  49. 49.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–45.CrossRefPubMedGoogle Scholar
  50. 50.
    ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies in retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.CrossRefGoogle Scholar
  51. 51.
    Keech, AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–97.CrossRefPubMedGoogle Scholar
  52. 52.
    DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–10.CrossRefGoogle Scholar
  53. 53.
    Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21:641–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844–50.CrossRefPubMedGoogle Scholar
  55. 55.
    Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis. 2003;41:S1–237.Google Scholar
  56. 56.
    Tonelli M, Collins D, Robins S, et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int. 2004;66:1123–30.CrossRefPubMedGoogle Scholar
  57. 57.
    Ting RD, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012;35:218–25.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease. A systematic review and meta-analysis. J Am Coll Cardiol. 2012;60:2061–71.CrossRefPubMedGoogle Scholar
  59. 59.
    Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2010;54:280–90.CrossRefPubMedGoogle Scholar
  60. 60.
    Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012;35:1008–14.CrossRefPubMedCentralPubMedGoogle Scholar
  61. 61.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.CrossRefGoogle Scholar
  62. 62.
    Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin. 2003;19:155–168.CrossRefPubMedGoogle Scholar
  63. 63.
    Lipscombe J, Lewis GF, Cattran D, et al. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001;55:39–44.PubMedGoogle Scholar
  64. 64.
    Tonelli M, Collins D, Robins S, et al. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004;44:832–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000;15:1993–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Charach G, Grosskopf I, Rotmensch HH, et al. Bezafibrates cause moderate, reversible impairment in renal function in patients without prior renal disease. Nephron Clin Pract. 2005;100:c120–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Rizos E, Bairaktari E, Ganotakis E, et al. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther. 2002;7:219–26.CrossRefPubMedGoogle Scholar
  68. 68.
    Ansquer JC, Dalton RN, Causse E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51:904–13.CrossRefPubMedGoogle Scholar
  69. 69.
    Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45:485–93.CrossRefPubMedGoogle Scholar
  70. 70.
    Hottelart C, el Esper N, Achard JM, et al. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie. 1999;20:41–4.PubMedGoogle Scholar
  71. 71.
    Hottelart C, el Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92:536–41.CrossRefPubMedGoogle Scholar
  72. 72.
    Chen YL, Hsu CY, Huang WC, et al. Fenofibrate reversibly increases serum creatinine level in chronic kidney disease patients by reducing glomerular filtration rate. Acta Nephrol. 2011;25:1–4.Google Scholar
  73. 73.
    Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585–90.CrossRefPubMedGoogle Scholar
  75. 75.
    Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71–5.CrossRefPubMedGoogle Scholar
  76. 76.
    Jones PH, Davidson MHl. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Amer J Cardiol. 2005;95:120–2.CrossRefPubMedGoogle Scholar
  77. 77.
    de Lorgeril M, Salen P, Paillard F, et al. Lipid-lowering drugs and homocysteine. Lancet. 1999;353:209–10.CrossRefPubMedGoogle Scholar
  78. 78.
    Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999;354:219–20.CrossRefPubMedGoogle Scholar
  79. 79.
    Mayer O Jr, Simon J, Holubec L, et al. Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients. Eur J Cardiovasc Prev Rehabil. 2004;11:244–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet. 2001;358:39–40.CrossRefPubMedGoogle Scholar
  81. 81.
    Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–57.CrossRefPubMedGoogle Scholar
  82. 82.
    Eikelboom JW, Lonn E, Genest Jr J, et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363–75.CrossRefPubMedGoogle Scholar
  83. 83.
    Bissonnette R, Treacy E, Rozen R, et al. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis. 2001;155:455–62.CrossRefPubMedGoogle Scholar
  84. 84.
    Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Amer J Cardiol. 2004;93:848–53.CrossRefPubMedGoogle Scholar
  85. 85.
    Giral P, Bruckert E, Jacob N, et al. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis. 2001;154:421–7.CrossRefPubMedGoogle Scholar
  86. 86.
    Landray MJ, Townend JN, Martin S, et al. Lipid-lowering drugs and homocysteine. Lancet. 1999;353:1974–5.CrossRefPubMedGoogle Scholar
  87. 87.
    Jonkers IJ, de Man FH, Onkenhout W, et al. Implication of fibrate therapy for homocysteine. Lancet. 1999;354:1208.CrossRefPubMedGoogle Scholar
  88. 88.
    Syvanne M, Whittall RA, Turpeinen U, et al. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis. 2004;172:267–72.CrossRefPubMedGoogle Scholar
  89. 89.
    Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997;96: 2137–43.CrossRefPubMedGoogle Scholar
  90. 90.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.CrossRefPubMedGoogle Scholar
  91. 91.
    Caroli-Bosc FX, Le Gall P, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci. 2001;46:540–4.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press 2015

Authors and Affiliations

  1. 1.Department of Medicine, Division of NephrologyUniversity of CalgaryAlbertaCanada
  2. 2.The George Institute for Global HealthSydneyAustralia

Personalised recommendations